- Home
- BKYI vs INM Comparison
BKYI vs INM Comparison
Compare BKYI & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- INM
- Stock Information
- Founded
- BKYI 1993
- INM 1981
- Country
- BKYI United States
- INM Canada
- Employees
- BKYI N/A
- INM N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- BKYI Technology
- INM Health Care
- Exchange
- BKYI Nasdaq
- INM Nasdaq
- Market Cap
- BKYI 3.2M
- INM 3.4M
- IPO Year
- BKYI 1997
- INM N/A
- Fundamental
- Price
- BKYI $1.73
- INM $4.95
- Analyst Decision
- BKYI
- INM
- Analyst Count
- BKYI 0
- INM 0
- Target Price
- BKYI N/A
- INM N/A
- AVG Volume (30 Days)
- BKYI 11.1M
- INM 26.6K
- Earning Date
- BKYI 11-14-2024
- INM 02-11-2025
- Dividend Yield
- BKYI N/A
- INM N/A
- EPS Growth
- BKYI N/A
- INM N/A
- EPS
- BKYI N/A
- INM N/A
- Revenue
- BKYI $7,292,394.00
- INM $4,960,506.00
- Revenue This Year
- BKYI $1.96
- INM N/A
- Revenue Next Year
- BKYI $9.65
- INM N/A
- P/E Ratio
- BKYI N/A
- INM N/A
- Revenue Growth
- BKYI N/A
- INM 5.17
- 52 Week Low
- BKYI $0.52
- INM $2.42
- 52 Week High
- BKYI $3.68
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- BKYI 54.73
- INM 55.90
- Support Level
- BKYI $1.31
- INM $4.07
- Resistance Level
- BKYI $3.68
- INM $5.41
- Average True Range (ATR)
- BKYI 0.58
- INM 0.39
- MACD
- BKYI 0.04
- INM 0.01
- Stochastic Oscillator
- BKYI 23.53
- INM 67.83
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.